Phio Pharmaceuticals Announces Successful Completion of First Commercial-Scale cGMP Batch of PH-762 Drug Substance
Phio Pharmaceuticals Corp. (PHIO) filed an SEC Form 8-K — Other Events. Exhibit 99.1 Phio Pharmaceuticals Announces Successful Completion of First Commercial-Scale cGMP Batch of PH-762 Drug Substance Critical Manufacturing Milestone Supports Supply Chain Readiness and Planned Phase 2b Clinical Trial Initiation in First Quarter 2027 KING OF PRUSSIA, P
How this was made
The 30-second read
Why it matters
The cGMP batch validates the manufacturing process, a prerequisite for the Phase 2b trial slated for Q1 2027.
Market read
The announcement reduces a key risk factor for PHIO, potentially supporting a short‑term price uptick.
What to watch
Potential regulatory delays or scale‑up challenges could offset the manufacturing milestone.
Background
Phio Pharmaceuticals develops cancer therapeutics using its INTASYL siRNA platform. PH-762 targets the PD‑1 gene for skin cancers.
Ticker impact
Phio Pharmaceuticals announced the successful release of its first commercial-scale cGMP batch of PH-762 drug substance, a key manufacturing milestone that supports the upcoming Phase 2b trial.
likely upward pressure as investors price in reduced development risk
Milestone addresses a major operational hurdle, which typically improves market perception of biotech pipelines.
Market effects
Highlights progress in siRNA manufacturing, may boost confidence in similar biotech programs.
Limited to US biotech investors; no broader regional effect.
Minor; primarily relevant to specialty pharma and biotech investors.
Counterpoint
The batch may not translate to commercial success; clinical data still pending.
Key entities
- ExecutiveRobert Bitterman
President and CEO of Phio Pharmaceuticals, quoted on the milestone.
